ORLANDO, Fla., March 8 /PRNewswire-FirstCall/ -- Telzuit Medical Technologies, Inc. (the "Company" or "Telzuit") announced today that it has signed a co-marketing agreement with External Counter Pulsation (ECP) equipment maker Cardiomedics, Inc., for the sale of Telzuit's BioPatch Wireless Holter Monitor System through Cardiomedics' existing sales and marketing channels. Comprised of 26 internal and contracted sales staff, the Cardiomedics' sales force intends to market the BioPatch alongside Cardiomedics' ECP equipment, including the successful CardiAssist and CardiAssess Systems. With a client base of more than 500 cardiologists, Cardiomedics expects to place several thousand BioPatch units into the market within the first 12 months of usage. Terms of the agreement were not disclosed.
Donald Sproat, President and CEO of Telzuit, commented, "This is another key step in our efforts to support a successful formal launch of the BioPatch. Through this agreement we will leverage Cardiomedics strong client base and proven sales force to expand the sales and distribution of the BioPatch. Cardiomedics carries a distinguished reputation in the outpatient heart disease treatment market, and its successful ECP products provide a complementary sales platform for the BioPatch System. As always, we will continue to pursue alternative sales and distribution opportunities that will bolster our internal sales effort and increase the BioPatch's market reach and growth potential."
John Macallum, COO of Cardiomedics, commented, "The BioPatch serves as a natural complement to our line of ECP products, and we have witnessed solid pre-launch demand for the BioPatch's wireless Holter technology and favorable economic model. This partnership represents a win-win for both companies, and we look forward to a successful relationship with the Telzuit team."
Telzuit and Cardiomedics will display the BioPatch Wireless Holter Monitor System at the American College of Cardiology's 55th Annual Scientific Session, being held March 11-14, 2006, at the Georgia World Congress Center in Atlanta, Ga. The BioPatch will be displayed within the Cardiomedics' exhibit booth #4018. The Annual Scientific Session is attended by professionals involved in delivering cardiovascular care, including physicians, scientists, nurse practitioners, physician assistants and nurses. In addition to this core audience, medical students and trainees, technicians, dietitians, administrators and other healthcare professionals will all be in attendance at the various sessions and exhibits.
About Telzuit Medical Technologies, Inc.
Telzuit Medical Technologies, Inc. is dedicated to providing advanced mobile medicine for people worldwide. The first step in this mission will initially take the form of our state-of-the-art, FDA approved, Bio-Patch Wireless Heart Monitor. This is a full 12-lead, completely wireless, Holter monitor, which is new to the marketplace. Telzuit anticipates that the product will be available to patients and physicians, and the Cardiac Monitoring Center will open, by December 2005. Telzuit is also building its own dedicated intranet as a platform to handle several of the products it will be releasing, including its initial product, the Bio-Patch Wireless Heart Monitor System. Telzuit is based in Orlando, Florida. For more information on the company, its business model, and its products can be found on its Web site: http://www.telzuit.com .
About Cardiomedics, Inc
Founded in 1986, Irvine, California-based Cardiomedics, Inc. is engaged in the development, manufacturing and marketing of a portable, sequential, external counter pulsation (ECP) system (the "CardiAssist System"). The Company traces its roots back to the original inventors of external counter pulsation at Harvard/MIT. Medical Innovations, Inc. who first patented a device, was acquired by the CardiAssist Corporation, which in turn was acquired by Cardiomedics, Inc. in 1986. The CardiAssist System was cleared for sale in the United States under a 510(k) notification by the U.S. Food and Drug Administration ("FDA") for the treatment of acute myocardial infarction, angina pectoris ("Angina") and cardiogenic shock on September 18, 1987. On August 8, 2002, FDA cleared ECP for sale for the treatment of Congestive Heart Failure ("CHF"). ECP is a non-invasive technique to improve heart function.
Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties, including the effect of changing economic conditions, competition within the health products industry, customer acceptance of products, and other risks and uncertainties. Such forward-looking statements are not guarantees of performance, and Telzuit results could differ materially from those contained in such statements. These forward-looking statements speak only as of the date of this release, and Telzuit undertake no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.
Telzuit Medical Technologies, Inc
Senior Vice President
Brainerd Communicators, Inc.
Jennifer Gery (Media)
Todd St. Onge (Investors)
Chief Operating Officer
Telzuit Medical Technologies, Inc.